Skip to main content
main-content

01.01.2012 | Original Article | Ausgabe 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours

Zeitschrift:
European Journal of Nuclear Medicine and Molecular Imaging > Ausgabe 1/2012
Autoren:
Nils F. Schreiter, Winfried Brenner, Munenobu Nogami, Ralph Buchert, Alexander Huppertz, Ulrich-Frank Pape, Vikas Prasad, Bernd Hamm, Martin H. Maurer

Abstract

Purpose

Although somatostatin receptor positron emission tomography (PET)/CT is gaining increasing popularity and has shown its diagnostic superiority in several studies, 111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide is still the current standard for diagnosis of neuroendocrine tumours (NET). The aim of this study was to compare the costs for the two diagnostic tests and the respective consequential costs.

Methods

From January 2009 to July 2009, 51 consecutive patients with enteropancreatic NET who underwent contrast-enhanced 68Ga-DOTATOC PET/CT (n = 29) or 111In-DTPA-octreotide (mean 3 whole-body scans plus 1.6 low-dose single photon emission computed tomography/CT; n = 22) were included. For cost analysis, direct costs (equipment) and variable costs (material, labour) per examination were calculated. Additionally required CT and/or MRI examinations within the staging process were assessed as consequential costs. An additional deterministic sensitivity analysis was performed.

Results

A 68Ga-DOTATOC PET/CT examination yielded total costs (equipment, personnel and material costs) of 548 €. On the other hand, an 111In-DTPA-octreotide examination resulted in 827 € total costs. Costs for equipment and material had a share of 460 €/720 € for 68Ga-DOTATOC/111In-DTPA-octreotide and labour costs of 89 €/106 €. With 68Ga-DOTATOC additional MRI had to be performed in 7% of the patients resulting in a mean of 20 € for supplementary imaging per patient; 82% of patients with 111In-DTPA-octreotide needed additional MRI and/or CT resulting in mean additional costs of 161 € per patient.

Conclusion

68Ga-DOTATOC PET/CT was considerably cheaper than 111In-DTPA-octreotide with respect to both material and personnel costs. Furthermore, by using 68Ga-DOTATOC PET/CT considerably fewer additional examinations were needed reducing the consequential costs significantly.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.